Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famciclovir SCHEMBL29357294 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL8190642 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL2949 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL6471750 | 0.88 | KDM4E (0.94) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL3932051 | 0.88 | KDM4E (0.98) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL29098544 | 0.88 | KDM4E (0.98) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL6471652 | 0.88 | KDM4E (0.98) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL7103048 | 0.88 | KDM4E (0.98) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL1880119 | 0.86 | KDM4E (0.69) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL14163778 | 0.86 | KDM4E (0.89) | KDM4EALDH1A1HPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | claimed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-5246937-A | Viricides, herpes simplex | BEECHAM GROUP P.L.C. (GB) | 1993-09-21 | — | — | US | claimed |
| EP-0182024-B1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | BEECHAM GROUP PLC (GB) | 1991-04-03 | — | — | EP | claimed |
| WO-1987005604-A1 | 2-AMINOPURINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BEECHAM GROUP P.L.C. (GB) | 1987-09-24 | — | — | WO | claimed |
| EP-0182024-A2 | Purine derivatives and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1986-05-28 | — | — | EP | claimed |
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | disclosed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | QUADEX PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC | 2015-12-03 | — | — | US | disclosed |
| US-9125911-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-20140274939-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20060135464-A1 | Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues | QUADEX PHARMACEUTICALS, LLC | 2006-06-22 | — | — | US | disclosed |
| US-5559114-A | Treatment of autoimmune disease using 2-amino purine derivatives | EXLEY RAY W (US) | 1996-09-24 | — | — | US | disclosed |
| US-5250688-A | Treating herpes virus infections | BEECHAM GROUP P.L.C. (GB) | 1993-10-05 | — | — | US | disclosed |
| US-5246937-A | Viricides, herpes simplex | BEECHAM GROUP P.L.C. (GB) | 1993-09-21 | — | — | US | disclosed |
| EP-0182024-B1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | BEECHAM GROUP PLC (GB) | 1991-04-03 | — | — | EP | disclosed |
| WO-1987005604-A1 | 2-AMINOPURINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BEECHAM GROUP P.L.C. (GB) | 1987-09-24 | — | — | WO | disclosed |
| EP-0182024-A2 | Purine derivatives and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1986-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274939-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | SAMHD1, DCTD, NT5E | KDM4E 3252/4885ALDH1A1 3928/4885HPGD 3017/4885 |
| US-20060135464-A1 | Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues | DCTD, ADA, TYMP | KDM4E 3762/4885ALDH1A1 3858/4885HPGD 607/4885 |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | NT5E, SAMHD1, DCTD | KDM4E 2688/4885ALDH1A1 3897/4885HPGD 2762/4885 |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | SAMHD1, CUTA, TK1 | KDM4E 3024/4885ALDH1A1 4317/4885HPGD 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.